T he past 5 years have witnessed a watershed moment in the management of metastatic melanoma. Te successes of molecularly targeted and immune-based therapies have transformed it from an aggressively lethal malignancy into one that is readily treatable. Here, we discuss continued eforts to fnd new therapies and broaden the clinical impact of existing options to maintain the unprecedented momentum of improving patient outcomes.
Taking aim at oncogenic drivers
Decades of intense research eforts in melanoma have enabled researchers to pin down some of the molecular drivers of this disease and unraveled its complex relationship with the immune system. Tis has dramatically altered the treatment landscape in the past 5 years, with almost a dozen new treatment options coming to market, many of which have had an unprecedented impact on patient survival, and with many more in clinical development.
Te most signifcantly mutated gene in melanoma is BRAF, which encodes a serine-threonine protein kinase involved in the mitogen-activated protein kinase (MAPK) pathway (Figure 1 ), an important mediator of cell growth and proliferation. BRAF is mutated in about half of all patients with melanoma, generating a mutant kinase that is always active and drives aberrant MAPK signaling.
A number of other components of the MAPK pathway are altered in melanoma, including activating mutations in the upstream RAS enzyme, and loss of the neurofbromin 1 (NF1) gene, which is a negative regulator of RAS. Te discovery of this pathway as a key oncogenic driver of melanoma prompted the development of drugs to specifcally target it. 1, 2 First to arrive on the scene were vemurafenib and dabrafenib, two specifc inhibitors of mutant BRAF kinase. Both drugs elicited impressive response rates and improved progression-free survival (PFS) in patients with BRAF-mutant disease compared with those receiving chemotherapy, which resulted in their approval by the US Food and Drug Administration (FDA) in 2011 and 2013, respectively. 3, 4 Attempts to target other components of the MAPK pathway culminated in the successful development of inhibitors of MEK kinase, which sits immediately downstream of BRAF. Trametinib was approved by the FDA in 2013 for the treatment of BRAF-mutant metastatic melanoma, based on a 4-month improvement in survival over chemotherapy. 5 Tough BRAF and MEK inhibitors represent transformative treatment options, not all patients have mutations in the MAPK pathway. Tey are common in melanomas arising from nonchronically sun-damaged skin, but signifcantly less so in other types of melanoma, such as acral, mucosal, and vulvo-vaginal melanomas. Activating mutations of KIT have been identifed in a signifcant proportion of patients with these subtypes and multikinase inhibitors, such as imatinib, dasatinib and sunitinib, have shown clinical activity in these patients, with clinical trials ongoing (Table 1) . 6 Immunotherapy achieves durable control Melanoma has been the poster child of immunotherapy -cancer drugs that boost the antitumor immune response rather than directly killing the tumor. Te success is explained at least in part by the hypermutability of these tumors, which makes them strongly immunogenic. 2, 7 Tough numerous types of immunotherapy have been tested, the most promising are the immune checkpoint inhibitors that have now been widely embraced (Figure 2 ).
Tese drugs are designed to target one of the mechanisms cancer cells use to subvert the immune response mounted against them. Immune checkpoints are receptors expressed on the surface of immune cells that coordinate the activation of T cells in response to specifc antigens. Cancer cells manipulate their expression to suppress T-cell activity, efectively masking themselves from the immune system. 8 Te drug that launched the immune checkpoint Jane de Lartigue, PhD inhibitor era was ipilimumab, an inhibitor of cytotoxic T-lymphocyte antigen 4 (CTLA-4), which was awarded regulatory approval for the treatment of metastatic melanoma in 2011. Although the response rates were relatively low, they were astonishingly durable, with 60% of patients maintaining an objective response for at least 2 years. 9 Tat durability has been highlighted recently in longterm survival analyses. Pooled data from almost 2000 patients across different clinical trials demonstrated that more than 20% of patients survive 3 years after initiating treatment, and survival rates plateau after 2-3 years, with median 7-year overall survival (OS) of 17%, and some responses lasting up to 10 years. Te plateau efect was observed in several diferent large-scale analyses and occurred regardless of the dose, the type of previous treatment received, or BRAF mutation status. 10, 11 Ipilimumab became the frst check- 
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A second CTLA4-targeting antibody, tremelimumab, has also been developed, but has not proved as successful. Despite promise in early clinical trials, it did not improve OS when compared with standard chemotherapy in a phase 3 trial. 13 Several clinical trials are ongoing, however, and a recent analysis of long-term survival in 143 patients treated with tremelimumab suggested a pattern of longterm survival similar to that of ipilimumab. 14 Ipilimumab has largely been replaced in the front-line setting by antibodies that target a diferent immune checkpoint -the programmed cell death 1 (PD-1) receptor and its ligands, PD-L1 and PD-L2, largely as the result of the better safety profle and improved response rates observed with these drugs. Pembrolizumab and nivolumab were both originally approved in 2014 as second-line treatment options for patients who had progressed after treatment with ipilimumab or, in patients with BRAF mutations, after treatment with a BRAF inhibitor. 15, 16 In 2015, the FDA expanded the indications to allow their use in the front-line setting in BRAF wild-type patients, when both demonstrated improved efcacy compared with chemotherapy (in the nivolumab trial) and in a direct head-to-head comparison with ipilimumab in the case of pembrolizumab. Te nivolumab indication was further expanded to include patients with BRAF mutations. [17] [18] [19] More recently, researchers have begun to uncover more details of immune checkpoint signaling and the number of known modulators of T-cell function, and with it the number of potential drug targets, has grown. Drugs that target other inhibitory checkpoint pathways have been developed, but the alternative strategy of targeting stimulatory checkpoints, such as the lymphocyte activation gene (LAG3) and T-cell immunoglobulin and mucin protein 3 (TIM3), with agonists has also borne fruit, with numerous agents in the early stages of clinical testing ( Table 2) . 8 Tough immune checkpoint inhibition remains the most promising strategy, other ways of stimulating the immune system have been and continue to be evaluated. Terapeutic vaccines have been a major focus of research and a number of diferent approaches have been tested, including whole cell vaccines, dendritic cell vaccines, DNA vaccines, and peptide vaccines. Historically, vaccines have had limited efcacy in melanoma, however, a novel type of vaccine was recently approved by the FDA for the treatment of unre- Feature sectable melanoma after initial surgery. Talimogene laherparepvec (T-VEC) is an oncolytic herpes simplex virus type 1 (HSV-1)-based vaccine -the virus preferentially infects and destroys cancer cells by inducing immune responses against them and by directly disrupting metabolic processes. Among 436 patients, the durable response rate was higher in those receiving T-VEC than in those receiving granulocyte macrophage colony-stimulating factor (GM-CSF; 16.3% vs 2.1%, respectively). Te primary survival analysis was recently published and demonstrated improved OS for T-VEC compared with GM-CSF (median OS, 23.3 vs 18.9 months).
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Combination therapy maintains momentum
Despite the signifcant advances in targeted and immune therapies, many patients still succumb to melanoma as a result of the clinical limitations of these agents. On the one hand, targeted therapy can lead to rapid responses in a signifcant proportion of patients, but these are generally short-lived responses and tumors inevitably regrow as patients develop resistance. Immunotherapy, on the other hand, can lead to long-term survival benefts, but only a minority of patients respond. Te challenge now is to maintain momentum in melanoma research to not only develop new drugs, but to broaden the clinical impact of existing treatment modalities.
Signifcant research eforts have been focused on uncovering the mechanisms of resistance to targeted therapies. Best understood are changes that occur in the MAPK pathway that lead to reactivation of its efects, most commonly through alterations in the BRAF gene that prevent BRAF inhibitor binding. Alternatively, alterations in other components of the MAPK pathway, such as RAS or NF1, or activation of alternative pathways, including the phosphatidylinositol-3-kinase (PI3K) pathway, or of downstream efector proteins, most prominently the cyclin-dependent kinases (CDKs), can also drive resistance. 21 A number of therapeutic strategies have been developed to help overcome resistance. Several next-generation, more potent and specifc BRAF (eg, encorafenib) and MEK (eg, cobimetinib and binimetinib) inhibitors have been developed. Te results from the ongoing phase 3 NEMO trial of binimetinib compared with dacarbazine in NRAS-mutant melanoma were recently reported, and the study met its primary endpoint of improved PFS (2.8 vs 1.5 months, respectively). 22 For the most part, however, these drugs are 24, 25 Te combination of encorafenib and binimetinib has recently demonstrated efcacy in the ongoing phase 2 LOGIC2 trial, according to results presented at the 2015 European Society of Clinical Oncology meeting. Te response rate was 71% in previously untreated patients and 42% in patients who had received prior BRAF and/ or MEK inhibitor therapy. Adverse events were mostly grade 1/2 and included diarrhea, nausea, fatigue, and retinopathy. 26 Tis combination is also being evaluated in the phase 3 COLUMBUS trial. Other targeted therapies have been shown to act synergistically with BRAF inhibitors, and combination approaches undergoing clinical testing include with both PI3K and CDK inhibitors.
Combination therapy has also been fruitful for improving outcomes with immune checkpoint inhibitors, although it comes at the price of increased cost and toxicity. Nivolumab and ipilimumab became the frst combination immunotherapy to be awarded regulatory approval in 2015 and is approved for the same indications as nivolumab monotherapy. Tis combination has produced the highest response rates and OS to date in melanoma patients. In the CheckMate-069 study, it reduced the risk of progression or death by 60% compared with ipilimumab monotherapy, and the CheckMate-067 trial subsequently showed that those benefts were independent of BRAF-mutation status. 17 Many other combinations are being evaluated in clinical trials, including pairing drugs with diferent mechanisms of action, such as targeted therapy in combination with immunotherapy. Some studies are even investigating the potential of triplet therapy, though the efcacy has to be carefully weighed against the potential for increased toxicity. Te focus is on BRAF, MEK, and immune checkpoint drug combinations, but other rational groupings are being examined. In the second part of the LOGIC2 trial, the combination of encorafenib and binimetinib is being tested with other targeted drugs, including PI3K and CDK inhibitors, to determine potentially efective triplets.
A question of timing BRAF, MEK, and immune checkpoint inhibitors, along with several combinations all now provide potential options for front-line therapy of patients with melanoma (Table 2) . Te treatment landscape has evolved faster than guideline recommendations and important questions remain to be answered. A key consideration is which of these drugs is the optimal front-line therapy and whether it matters in what order the drugs are administered as frst-, second-, third-line, and so on, therapy.
Head-to-head comparisons have been limited thus far, and it is unclear which drugs should be the preferred choice in the front line. Tere are also no clear data about optimal sequencing -indeed, arguments can be made for and against each possible scenario. Findings from one study suggested that using targeted therapy frst can negatively infuence the response to an immune checkpoint inhibitor in the second-line, while the reverse is not true. Other fndings have proposed that BRAF inhibitors help to reduce the size of the tumor, making subsequent immunotherapy more efective. [27] [28] [29] Te situation is likely to be more nuanced and will need to be tailored to each situation and patient. Te current consensus is that patients with aggressive, high-volume, symptomatic disease are best treated with BRAF inhibitors frst, whereas those with indolent, low-volume, asymptomatic disease could be treated with upfront immunotherapy, but the availability of combination therapy now further complicates the situation. Sequencing and comparative studies are ongoing that should help to provide clarifcation.
